Inogen Announces Second Quarter 2025 Financial Results
INGNGOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Second Quarter 2025 Financial Results; Delivered strong top-line results; raising full year 2025 revenue expectations
Inogen Upgraded: Analyst Sees Growth, EBITDA Breakthrough
INGNNeedham's Mike Matson upgrades Inogen to Buy, citing turnaround progress, margin gains, and path to EBITDA breakeven by 2025.
Needham Upgrades Inogen to Buy, Announces $12 Price Target
INGNStifel Maintains Hold on Inogen, Lowers Price Target to $7
INGNInogen Sees Q2 Sales $89.000M-$91.000M vs $92.73M Est
INGNInogen Affirms FY2025 Sales Guidance of $352.00M-$355.00M vs $352.81M Est
INGNInogen Q1 Adj. EPS $(0.11) Beats $(0.50) Estimate, Sales $82.28M Beat $79.55M Estimate
INGNNeedham Reiterates Hold on Inogento Hold
INGNNeedham Reiterates Hold on Inogento Hold
INGNWhat's Going On With MedTech Focused Inogen Stock On Wednesday?
INGNInogen beat Q4 earnings and revenue estimates, citing strong B2B demand. Analysts see potential but flag supply challenges and restructuring risks.
Needham Reiterates Hold on Inogento Hold
INGNInogen Sees FY2025 Sales $352.000M-$355.000M vs $344.61M Est
INGNInogen Sees Q1 Sales $79.000M-$81.000M vs $78.08M Est
INGNInogen Q4 Adj $(0.24) Beats $(0.61) Estimate, Sales $80.08M Beat $73.91M Estimate
INGNNeedham Reiterates Hold on Inogento Hold
INGNInogen Estimates Preliminary FY24 Total Revenue Of $334.5M - $335.5M (Est $329.615M), Exceeding Prior Guidance Range Of $329M - $331M
INGNInogen Estimates Preliminary Q4 Total Revenue Of $79M - $80M, Reflecting YoY Growth Of 4% To 5%; Est $73.91M
INGN